Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients

  • End date
    Dec 28, 2024
  • participants needed
  • sponsor
    University Hospital, Antwerp
Updated on 28 January 2021


In this phase I/II trial, the primary objective is to determine overall and progression-free survival of patients with newly diagnosed glioblastoma when autologous Wilms' tumor 1 (WT1) messenger (m)RNA-loaded dendritic cell (DC) vaccination is added to adjuvant temozolomide maintenance treatment following (sub)total resection and temozolomide-based chemoradiation.


Glioblastoma multiforme (GBM), a microscopically infiltrative disease, is the most common malignant brain tumor worldwide. Despite optimized standard of care treatment median survival and prognosis remain poor with a median survival of only 15% and five year survival after diagnosis of 5%.

In this single arm single centre phase I/II trial the investigators will determine the overall and progression free survival of patients with newly diagnosed GBM when autologous WT1 mRNA loaded dendritic cell vaccination is added to standard of care treatment. During recruitment, the investigators will include 20 patients with newly diagnosed, histologically verified glioblastoma (WHO grade IV) who have received a total or subtotal resection of the tumor. Patients who underwent prior radiation or chemotherapy or with a history of other malignancy will be excluded. In addition to standard of care consisting of adjuvant chemoradiation with temozolomide and temozolomide maintenance patients will receive an intradermal vaccination with autologous WT1 mRNA-loaded dendritic cells commencing 1 week after radiotherapy. The dendritic cell therapy product will be generated and administered in the Antwerp University Hospital, more specifically the Center for Cell Therapy and Regenerative Medicine (CCRG) and the Division of Hematology, both headed by Prof. Zwi Berneman.

Recruitment began in December 2015 and is intended to continue until the end of 2020 or when 20 patients are enrolled. After a follow-up period (until 90 days after final DC vaccine administration or 24 months after apheresis , whichever occurs later), overall and progression free survival analysis will be performed and this will be compared with the published data of standard of care treatment without vaccination. In addition the investigators will look for feasibility, incidence of adverse events and immunogenicity.

Condition Glioblastoma Multiforme of Brain
Treatment Dendritic cell vaccine plus temozolomide chemotherapy
Clinical Study IdentifierNCT02649582
SponsorUniversity Hospital, Antwerp
Last Modified on28 January 2021


Yes No Not Sure

Inclusion Criteria

Newly diagnosed, histologically verified glioblastoma (WHO grade IV)
Aged 18 years
Total or subtotal resection
Total resection: macroscopic complete resection as assessed by the neurosurgeon and absence of any residual contrast-enhancing mass on post-operative ( 72h) brain MRI
Subtotal resection: macroscopic complete resection as assessed by the neurosurgeon, but with residual contrast-enhancement 2 cm on post-operative ( 72h) brain MRI
Signed informed consent
Willing and able to comply with the protocol as judged by the Investigator
Estimated to start with chemoradiation 28 days and 49 days following surgical resection
Fit to undergo: leukapheresis, chemoradiation, chemotherapy and immunotherapy
No corticosteroid treatment 1 week before apheresis
WHO performance status 2
Life expectancy 3 months as estimated by the Investigator

Exclusion Criteria

History of another malignancy, except for adequately controlled basal cell skin carcinoma, squamous skin carcinoma, or carcinoma in situ of the uterine cervix or unless the investigator rationalizes otherwise
Prior radiation or chemotherapy
Any pre-existing contraindication for temozolomide treatment
Any pre-existing contraindication for contrast-enhanced brain MRI
Pregnant or breast-feeding
Documented immune deficiency or systemic immune-suppressive treatment
Known positive viral serology for HIV, HBV, HCV, or syphilis
Any other condition, either physical or psychological, or reasonable suspicion thereof on clinical or special investigation, which contraindicates the use of the vaccine, or may negatively affect patient compliance, or may place the patient at higher risk of potential treatment complications
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note